Capsule Summary Slidesets

Share

Program Content

Activities

  • OPTIC: Ponatinib Dosing
    OPTIC: A Phase II Dose-Optimization Trial Evaluating 3 Different Starting Doses of Ponatinib in CP-CML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2021

    Expires: June 07, 2022

  • ZUMA-3: Brexu-cel for ALL
    ZUMA-3: Phase II Results With Brexucabtagene Autoleucel for Relapsed/Refractory Adult B-Cell ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2021

    Expires: June 07, 2022

  • Enasidenib in High-Risk IDH2-Mut MDS
    Phase II Study of IDH2 Inhibitor Enasidenib in Patients With High-Risk IDH2-Mutated MDS
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2021

    Expires: June 06, 2022

  • VEN-AZA in Secondary AML
    Venetoclax + Azacitidine vs Azacitidine Monotherapy in Chemotherapy-Ineligible Patients With tAML or AML From Antecedent MDS or CMML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2021

    Expires: June 05, 2022

  • QUAZAR AML-001 MV Analysis
    QUAZAR AML-001 Multivariate Analysis: Predictors of Survival Outcomes With Oral Azacitidine (CC-486) Among Patients With AML in Remission After Intensive Chemotherapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2021

    Expires: June 09, 2022

  • AML: MRD Response and Prognosis
    MRD Response and Prognosis With Venetoclax + Azacitidine in Patients With AML Ineligible for Intensive Induction Chemotherapy From the VIALE-A Trial
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2021

    Expires: June 06, 2022

  • ELEVATE-RR
    ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2021

    Expires: June 08, 2022

  • CAPTIVATE FD Cohort
    CAPTIVATE: Primary Analysis From the Fixed-Duration Cohort of First-line Ibrutinib + Venetoclax for CLL/SLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2021

    Expires: June 10, 2022

  • Venetoclax + Len/R in MCL
    Phase Ib Trial of Venetoclax, Lenalidomide, and Rituximab in Untreated Mantle Cell Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 16, 2021

    Expires: June 15, 2022

  • ELARA: Tisa-cel for R/R FL
    ELARA: Efficacy and Safety of Tisagenlecleucel in Relapsed/Refractory Follicular Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2021

    Expires: June 10, 2022

  • ELEVATE-TN: 4-Yr Update
    ELEVATE-TN: 4-Year Follow-up Analysis of Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil for Treatment-Naive CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2021

    Expires: June 05, 2022

  • EPCORE NHL-1 Update
    EPCORE NHL-1: Update From First-in-Human Phase I/II Trial of Epcoritamab, an Anti-CD3/Anti-CD20 Bispecific Antibody, in R/R B-Cell NHL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2021

    Expires: June 06, 2022

  • FORTE: Analysis by Cytogenetic Risk
    FORTE Subanalysis: Efficacy of KRd With or Without ASCT Followed by KR or R Maintenance in Patients With ND MM According to Cytogenetic Risk Status
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2021

    Expires: June 10, 2022

  • CASSIOPEIA Part 2
    CASSIOPEIA Part 2: Daratumumab Maintenance or Observation After Treatment With VTd or D-VTd and ASCT in Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2021

    Expires: June 13, 2022

  • SC Elranatamab in R/R MM
    MagnetisMM-1: Efficacy, Safety, and Tolerability of Subcutaneous Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2021

    Expires: June 13, 2022

  • KarMMa Update: Ide-cel for R/R MM
    Updated Findings From the Phase II KarMMa Study of Idecabtagene Vicleucel for R/R Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2021

    Expires: June 06, 2022

  • ICARIA-MM Update
    ICARIA-MM: Second Interim Analysis of Phase III Study of Addition of Isatuximab to Pomalidomide and Low-Dose Dexamethasone in R/R Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2021

    Expires: June 08, 2022

  • Ixa + Dex vs Pom + Dex in R/R MM
    Randomized Phase II Trial of Ixazomib + Dexamethasone vs Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2021

    Expires: June 08, 2022

  • IKEMA: Isa-Kd in R/R MM
    IKEMA Subgroup Analyses: Isatuximab Plus Carfilzomib/Dex vs Carfilzomib/Dex in Patients With Relapsed/Refractory MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2021

    Expires: June 07, 2022

  • DREAMM-2 Ocular Toxicity
    DREAMM-2: Exploration of BCVA, Ocular Symptoms, and OSDI Questionnaire as Surrogates for Corneal Alterations During Treatment With Belantamab Mafodotin in R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2021

    Expires: June 04, 2022

  • IVO +VEN ± AZA
    Phase Ib/II Trial of Ivosidenib + Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme